Contact Us: 01282 426380
KM Financial Solutions | RPT-FOCUS-Amgen’s new migraine drug hits insurance hurdles
23738
post-template-default,single,single-post,postid-23738,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

RPT-FOCUS-Amgen’s new migraine drug hits insurance hurdles

25 Jul RPT-FOCUS-Amgen’s new migraine drug hits insurance hurdles

Posted at 11:00h in News by
0 Likes
Amgen Inc’s push to get
patients on its new $575 a month migraine drug before
competition emerges in September is facing barriers from
insurers.

No Comments

Sorry, the comment form is closed at this time.